The effectiveness of omalizumab in patients with severe chronic spontaneous urticaria (results of own clinical experience)

Cover Page
Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract


BACKGROUND: Urticaria is one of the most common dermatoses and affects 15–25% of the population; chronic spontaneous urticaria occur in 1.8% of adults and in 0.1–3% of children. Second generation antihistamines are effective only in 45–77% of patients. The next steps of treatment include increase antihistamines dose and their combination with omalizumab.

AIM: To analyze own clinical experience and assess effectiveness of omalizumab in severe chronic spontaneous urticaria.

MATERIALS AND METHODS: Effectiveness of biological treatment with omalizumab was analyzed in 14 patients with severe chronic spontaneous urticaria.

RESULTS: The prescription of omalizumab in the basic therapy of patients with severe chronic spontaneous urticaria (CSU) allowed to reduce significantly the severity of clinical symptoms in 78.6% of patients, to abandon the use of systemic glucocorticosteroids and to achieve partial or complete control of the disease. It should be noted, that 28.5% of patients during the immunobiological therapy stopped taking second-generation antihistamines and the dosage was reduced to therapeutic in 35.7% of patients.

CONCLUSION: Omalizumab is a highly effective in patients with severe chronic spontaneous urticaria.


Restricted Access

Olesya V. Skorokhodkina

Kazan State Medical University

Author for correspondence.
Email: olesya-27@rambler.ru
ORCID iD: 0000-0001-5793-5753

Russian Federation, Kazan

head of the Department of Clinical Immunology with Allergology of Kazan State Medical University, MD, PhD, professor

Aliya R. Klyucharova

Kazan State Medical University; Republican Clinical Hospital

Email: aliluia@yandex.ru
ORCID iD: 0000-0001-9045-5831

Russian Federation, Kazan

assistant, Department of Clinical Immunology with Allergology of Kazan State Medical University, MD, Phd, allergologist-immunologist

Alexey V. Luntsov

Republican Clinical Hospital

Email: luntsov@gmail.com
ORCID iD: 0000-0003-2552-2107

Russian Federation, Kazan

head of the Cеnter of Clinical Immunology, PhD, allergologist-immunologist

  1. Khaitov R.M., Il′ina N.I., editors. Allergologiya i klinicheskaya immunologiya. Klinicheskie rekomendatsii. Moscow: GEOTAR-Media; 2019. P. 214–241 (In Russ.).
  2. Kozel MM, Sabroe RA. Chronic urticaria: aetiology, management and current and future treatment options. Drugs. 2004;64(22):2515–2536. doi: 10.2165/00003495-200464220-00003
  3. Zuberbier T, Balke M, Worm M, Edenharter G, Maurer M. Epidemiology of urticaria: a representative cross-sectional population survey. Clin Exp Dermatol. 2010;35(8):869–873. doi: 10.1111/j.1365-2230.2010.03840.x
  4. Meshkova RY. Chronic spontaneous urticaria (part 1). Allergologiya i immunologiya v pediatrii. 2014;(1):12–17 (In Russ.).
  5. Kaplan AP, Greaves M. Pathogenesis of chronic urticaria. Clin Exp Allergy. 2009;39(6):777–787. doi: 10.1111/j.1365-2222.2009.03256.x
  6. Vonakis BM, Saini SS. New concepts in chronic urticaria. Curr Opin Immunol. 2008;20(6):709–716. doi: 10.1016/j.coi.2008.09.005
  7. Kolkhir P, Church MK, Weller K, Metz M, Schmetzer O, Maurer M. Autoimmune chronic spontaneous urticaria: What we know and what we do not know. J Allergy Clin Immunol. 2016;139(6):1772–1781. doi: 10.1016/j.jaci.2016.08.050
  8. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, Ballmer-Weber B, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397
  9. Criado R, Criado P, Martins J, Valente N, Michalany N, Vasconcellos C. Urticaria unresponsive to antihistaminic treatment: an open study of therapeutic options based on histopathologic features. J Dermatolog Treat. 2008;19(2):92–96. doi: 10.1080/09546630701499309
  10. grls.rosminzdrav.ru [Internet]. Instructions for medical use of Omalizumab [cited 2017 Jul 31]. Available from: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=60a93da4-4a06-425a-beb2-0a5ffdd6f4b2&t (In Russ.).
  11. Chang T, Chen C, Lin C, Metz M, Church M, Maurer M. The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. J Allergy Clin Immunol. 2015;135(2):337–342. doi: 10.1016/j.jaci.2014.04

Supplementary files

Supplementary Files Action
1. Fig. 1. Distribution of patients with HSC according to the control of symptoms of the disease during therapy with omalizumab View (180KB) Indexing metadata
2. Fig. 2. Changes in HCK indices in patients during the course of omalizumab (group I) View (50KB) Indexing metadata
3. Fig. 3. Changes in HCK indices in patients during the course of omalizumab (group II) View (30KB) Indexing metadata
4. Fig. 4. Changes in HCK indices in patients during the course of omalizumab (group III) View (28KB) Indexing metadata

Views

Abstract - 27

PDF (Russian) - 1

PlumX

Dimensions

Refbacks

  • There are currently no refbacks.

Copyright (c) 2020 Russian Allergological Journal

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies